• Allergy and Clinical Immunology
• Go, ladies, go, the goal is ahead!

  Publication date: Available online 19 October 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Mariana Castells

  Allergy and Clinical Immunology

  Sat Oct 19, 2019 04:26
• Identifying Regulatory Pathways of SYK Expression in Human Basophils

  Publication date: Available online 17 October 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Xia Peng, Mingming Zhao, Li Gao, Ranjan Sen, Donald MacGlashanAbstractBackgroundExpression levels of SYK, a critical signaling tyrosine kinase in basophils, are uniquely low relative to all other circulating leukocytes and levels are highly variable in the population.HypothesisTranscriptional regulation of SYK through unique silencing of

  Allergy and Clinical Immunology

  Fri Oct 18, 2019 07:30
• Early-life inhalant allergen exposure, filaggrin genotype and the development of sensitization from infancy to adolescence

  Publication date: Available online 17 October 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Angela Simpson, Helen A. Brough, Sadia Haider, Danielle Belgrave, Clare S. Murray, Adnan CustovicAbstractBackgroundWe hypothesized that filaggrin loss-of-function mutations modify the impact of allergen exposure on the development of allergic sensitization.ObjectiveTo determine whether early-life exposure to inhalant allergens increases

  Allergy and Clinical Immunology

  Fri Oct 18, 2019 07:30
• Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream

  Publication date: Available online 17 October 2019Source: Journal of Allergy and Clinical ImmunologyAuthor(s): Brian S. Kim, Michael D. Howell, Kang Sun, Kim Papp, Adnan Nasir, Michael E. Kuligowski, INCB 18424-206 Study InvestigatorsAbstractBackgroundAtopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase (JAK)-1 and JAK2, potently suppresses cytokine signaling involved i

  Allergy and Clinical Immunology

  Fri Oct 18, 2019 07:30
• Autoimmunity Reviews
• Does seronegative obstetric APS exist? “pro” and “cons”

  Publication date: Available online 19 October 2019Source: Autoimmunity ReviewsAuthor(s): Fabrizio Conti, Laura Andreoli, Francesca Crisafulli, Silvia Mancuso, Simona Truglia, Maria G. TektonidouAbstractAntiphospholipid Syndrome (APS) is the commonest treatable cause of recurrent miscarriage and pharmacological treatment of pregnant patients with antiphospholipid antibodies (aPL) should aim at preventing obstetric complications and maternal thromb

  Autoimmunity Reviews

  Sat Oct 19, 2019 15:06
• Is there today a place for corticosteroids in the treatment of scleroderma?

  Publication date: Available online 19 October 2019Source: Autoimmunity ReviewsAuthor(s): Jelena Blagojevic, Paul Legendre, Marco Matucci-Cerinic, Luc MouthonAbstractIn systemic sclerosis (SSc), the use of corticosteroids (CS) is controversial due to their association with scleroderma renal crisis (SRC). However, patients with very early and early disease, characterised by main inflammatory component, may benefit from CS therapy.The aim of this re

  Autoimmunity Reviews

  Sat Oct 19, 2019 15:06
• Biosimilars vs originators: Are they the same?

  Publication date: Available online 19 October 2019Source: Autoimmunity ReviewsAuthor(s): Piercarlo Sarzi-Puttini, Daniela Marotto, Roberto Caporali, Mauro Galeazzi, Fabiola Atzeni, Attila Hamar, Boglárka Soós, Zoltán SzekaneczAbstractBiological drugs have revolutionised the treatment of rheumatic diseases, and the recent expiry of the patents for many biological agents has generated considerable interest among pharmaceutical companies and regulat

  Autoimmunity Reviews

  Sat Oct 19, 2019 15:06